New drug trial aims to keep kidney patients' potassium in check
NCT ID NCT05136664
Summary
This study tested a medication called patiromer in Chinese adults with chronic kidney disease and high potassium levels. The goal was to see if patiromer could safely and effectively lower potassium, allowing patients to continue taking their important heart and kidney medications. The trial involved an initial treatment period followed by a withdrawal phase to see if potassium levels rose again when the drug was stopped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigator Site 001
Hangzhou, Zhejiang, 310003, China
-
Investigator Site 002
Changzhou, Jiangsu, 213004, China
-
Investigator Site 003
Lanzhou, Gansu, 730030, China
-
Investigator Site 004
Chengdu, Sichuan, 610044, China
-
Investigator Site 005
Xuzhou, Jiangsu, 221004, China
-
Investigator Site 006
Changsha, Hunan, 410013, China
-
Investigator Site 007
Changchun, Jilin, 130041, China
-
Investigator Site 008
Hefei, Anhui, 230601, China
-
Investigator Site 009
Hefei, Anhui, 230022, China
-
Investigator Site 010
Wuhan, Hubei, 430060, China
-
Investigator Site 011
Yuncheng, Shanxi, 044099, China
-
Investigator Site 012
Lanzhou, Gansu, 730013, China
-
Investigator Site 013
Zhenjiang, Jiangsu, 210031, China
-
Investigator Site 014
Tianjin, Tianjin Municipality, 300052, China
-
Investigator Site 015
Shanghai, Shanghai Municipality, 200040, China
-
Investigator Site 016
Beijing, Beijing Municipality, 100029, China
-
Investigator Site 018
Yinchuan, Ningxia, 750003, China
-
Investigator Site 019
Nanjing, Jiangsu, 210029, China
-
Investigator Site 020
Hanzhou, Zhejiang, 310014, China
-
Investigator Site 021
Wuxi, Jiangsu, 214023, China
-
Investigator Site 022
Taiyuan, Shanxi, 030012, China
-
Investigator Site 023
Ürümqi, Xinjiang, 830001, China
-
Investigator Site 024
Nanyang, Henan, 473000, China
-
Investigator Site 025
Jinhua, Zhejiang, 322000, China
-
Investigator Site 026
Jiaxing, Zhejiang, 314000, China
-
Investigator Site 027
Zhuzhou, Tianyuan District, 412007, China
-
Investigator Site 028
Shanghai, Pudong New Area, 200120, China
-
Investigator Site 029
Guangzhou, Guangdong, 510060, China
-
Investigator Site 030
Nanning, Guangxi, 530000, China
Conditions
Explore the condition pages connected to this study.